Cargando…

Denosumab – a new medication in the treatment of postmenopausal osteoporosis

Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It leads to an increased risk of bone fractures – one of the major causes of disability in modern societies. Bisphosphonates are the most commonly used medications in the treatment of postmenopausal osteop...

Descripción completa

Detalles Bibliográficos
Autores principales: Słopień, Radosław, Rynio, Piotr, Kubala, Elżbieta, Milewska, Ewa, Meczekalski, Blazej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834919/
https://www.ncbi.nlm.nih.gov/pubmed/29507572
http://dx.doi.org/10.5114/pm.2017.70581
_version_ 1783303736909627392
author Słopień, Radosław
Rynio, Piotr
Kubala, Elżbieta
Milewska, Ewa
Meczekalski, Blazej
author_facet Słopień, Radosław
Rynio, Piotr
Kubala, Elżbieta
Milewska, Ewa
Meczekalski, Blazej
author_sort Słopień, Radosław
collection PubMed
description Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It leads to an increased risk of bone fractures – one of the major causes of disability in modern societies. Bisphosphonates are the most commonly used medications in the treatment of postmenopausal osteoporosis. Denosumab, a new approach to fracture prevention, is a fully human monoclonal antibody that targets nuclear factor-κB ligand (RANKL), an important cytokine regulating formation and function of osteoclasts. Generally, denosumab is not used as initial therapy; however, in some cases it should be considered. It concerns patients at high risk of fracture, such as older patients who have difficulty with the dosing requirements of oral bisphosphonates or who have markedly impaired renal function. Denosumab can be also considered in patients who present intolerance or unresponsiveness to other therapies. Clinical studies have shown that denosumab is highly effective in increasing bone mineral density (BMD) in postmenopausal women regardless of the site analysed, as well as reducing the risk of bone fractures. The risk of developing antiresorptive, agent-induced osteonecrosis of the jaw related to denosumab therapy is low.
format Online
Article
Text
id pubmed-5834919
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-58349192018-03-05 Denosumab – a new medication in the treatment of postmenopausal osteoporosis Słopień, Radosław Rynio, Piotr Kubala, Elżbieta Milewska, Ewa Meczekalski, Blazej Prz Menopauzalny Featured Paper Osteoporosis is a chronic, systemic skeletal disorder characterised by decreased bone density. It leads to an increased risk of bone fractures – one of the major causes of disability in modern societies. Bisphosphonates are the most commonly used medications in the treatment of postmenopausal osteoporosis. Denosumab, a new approach to fracture prevention, is a fully human monoclonal antibody that targets nuclear factor-κB ligand (RANKL), an important cytokine regulating formation and function of osteoclasts. Generally, denosumab is not used as initial therapy; however, in some cases it should be considered. It concerns patients at high risk of fracture, such as older patients who have difficulty with the dosing requirements of oral bisphosphonates or who have markedly impaired renal function. Denosumab can be also considered in patients who present intolerance or unresponsiveness to other therapies. Clinical studies have shown that denosumab is highly effective in increasing bone mineral density (BMD) in postmenopausal women regardless of the site analysed, as well as reducing the risk of bone fractures. The risk of developing antiresorptive, agent-induced osteonecrosis of the jaw related to denosumab therapy is low. Termedia Publishing House 2017-10-12 2017-09 /pmc/articles/PMC5834919/ /pubmed/29507572 http://dx.doi.org/10.5114/pm.2017.70581 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Featured Paper
Słopień, Radosław
Rynio, Piotr
Kubala, Elżbieta
Milewska, Ewa
Meczekalski, Blazej
Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title_full Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title_fullStr Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title_full_unstemmed Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title_short Denosumab – a new medication in the treatment of postmenopausal osteoporosis
title_sort denosumab – a new medication in the treatment of postmenopausal osteoporosis
topic Featured Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834919/
https://www.ncbi.nlm.nih.gov/pubmed/29507572
http://dx.doi.org/10.5114/pm.2017.70581
work_keys_str_mv AT słopienradosław denosumabanewmedicationinthetreatmentofpostmenopausalosteoporosis
AT ryniopiotr denosumabanewmedicationinthetreatmentofpostmenopausalosteoporosis
AT kubalaelzbieta denosumabanewmedicationinthetreatmentofpostmenopausalosteoporosis
AT milewskaewa denosumabanewmedicationinthetreatmentofpostmenopausalosteoporosis
AT meczekalskiblazej denosumabanewmedicationinthetreatmentofpostmenopausalosteoporosis